Dr. Charles Edward Dye, MD

Dr. Dye practices at Pshmg Briarcrest (Diabetes & Weight) - HOPD in Hershey, Pennsylvania.

Dr. Dye's NPI, 1326100884, was assigned on December 14, 2006. Dr. Dye graduated from Pennsylvania State University College of Medicine in 1995. Dr. Dye holds Pennsylvania license MD435401.

Dr. Dye's primary practice is Pshmg Briarcrest (Diabetes & Weight) - HOPD, at 905 W Governor Rd, Hershey, PA 17033.

Dr. Dye's primary practice is Pshmg Briarcrest (Diabetes & Weight) - HOPD in Hershey, Pennsylvania. Dr. Dye is also affiliated with Penn State Health Milton S. Hershey Medical Center. The medical group on file is Penn State Health Milton S. Hershey Medical Center. Dmand AI also links Dr. Dye to 1 more ambulatory surgery center, named with a free account. Dr. Dye's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dye practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Dye's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Dye's licenses on file in 2 states: Pennsylvania and Illinois.

CMS data shows 154 Medicare services from Dr. Dye across 6 procedure codes in 2024, for 221 Medicare patients. Medicare paid $18,837 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 221 Medicare patients who saw Dr. Dye in 2024. The largest group is 65 to 74, with 111 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dye's median patient age at 67, with 49% women.

In 2024, Dr. Dye wrote 320 Medicare Part D claims for 113 patients. 89% of them were for generic drugs. CMS names the drug for 232 of them, across 9 drugs with 11 or more claims each, at $21,717 in total drug cost. In 2023, CMS named 209 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Dye for performance year 2024, reported as part of a group. Dr. Dye accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 156 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Dye, more than 86% of the clinicians it reports for that procedure.

Dmand AI links 22 papers to Dr. Dye, published from 2011 to 2024. 2015 was the busiest year, with 3. The most frequent topics are Cholangiopancreatography, Endoscopic Retrograde and Constriction, Pathologic. Dr. Dye has published most often in Endosc Int Open. Dr. Dye's most frequent co-authors are John Maynard Levenick, MD, Thomas J. McGarrity, MD and Niraj Jaysukh Gusani, MD.

Dmand AI links Dr. Dye to 1 clinical trial. Conditions studied include Colonic Polyps and Intestinal Polyps.

CMS Open Payments shows 2 general payments to Dr. Dye from 2 drug and device companies from 2017 to 2022. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $18.

Dr. Dye graduated from Pennsylvania State University College of Medicine in 1995.